AZD-9291 mesylate CAS:1421373-66-1

AZD-9291 mesylate has significant applications in oncology and cancer treatment: NSCLC Treatment: Approved for the treatment of locally advanced or metastatic NSCLC harboring EGFR T790M mutation, which is resistant to first-generation EGFR inhibitors. Second-line Therapy: Used as a second-line treatment option for patients who have developed resistance to previous EGFR inhibitor therapies. Clinical Trials: Investigated in clinical trials for its efficacy in other EGFR-mutated cancers and as part of combination therapies with other targeted agents or immunotherapies. Precision Medicine: Represents a paradigm shift towards precision medicine, where treatments are tailored based on the genetic profile of the tumor, leading to improved outcomes and reduced side effects. Drug Development: Stimulates research into developing novel EGFR inhibitors and combination therapies to overcome resistance mechanisms and enhance treatment efficacy. Biomarker Studies: Utilized in studies aimed at identifying predictive biomarkers of response and resistance to EGFR-targeted therapies, guiding treatment decisions and personalized medicine approaches. In summary, AZD-9291 mesylate is a targeted therapy drug that has revolutionized the treatment landscape for NSCLC patients with EGFR mutations. Its applications extend beyond NSCLC, fueling ongoing research and innovation in precision oncology and personalized cancer treatment strategies.